Vaxart (OTCMKTS:VXRT) Shares Pass Above 50 Day Moving Average - Here's What Happened

Key Points

• Shares crossed above their 50‑day moving average (50‑day MA $0.66), trading as high as $0.75 and last at $0.6910 on volume of 494,037 shares.
• Quarterly results beat expectations: Vaxart reported EPS of $0.24 versus a consensus of ($0.08) and revenue of $104.24M versus $35.95M estimated, with a net margin of 6.88% and ROE of 33.83%.
• Analyst/institutional support is rising: Wall Street Zen upgraded the stock to a "buy" and several institutions (including Jones, Invesco and Marshall Wace) added positions, leaving institutions with about 18.05% ownership.

Shares of Vaxart, Inc. (OTCMKTS:VXRT - Get Free Report) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.66 and traded as high as $0.75. Vaxart shares last traded at $0.6910, with a volume of 494,037 shares changing hands.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Vaxart to a "buy" rating in a report on Friday, January 23rd.

Vaxart Price Performance

The stock has a fifty day moving average of $0.66 and a 200 day moving average of $0.50. The firm has a market capitalization of $166.81 million, a P/E ratio of 11.52 and a beta of 1.31.

Vaxart (OTCMKTS:VXRT - Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The biotechnology company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.32. The business had revenue of $104.24 million for the quarter, compared to analyst estimates of $35.95 million. Vaxart had a return on equity of 33.83% and a net margin of 6.88%. Equities analysts forecast that Vaxart, Inc. will post -0.39 EPS for the current fiscal year.

Institutional Trading of Vaxart

Hedge funds have recently bought and sold shares of the business. Creative Planning bought a new stake in Vaxart during the second quarter worth $33,000. Raymond James Financial Inc. raised its stake in shares of Vaxart by 16.9% in the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company's stock valued at $107,000 after buying an additional 34,075 shares during the period. Jones Financial Companies Lllp raised its stake in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock valued at $196,000 after buying an additional 478,111 shares during the period. Marshall Wace LLP bought a new stake in shares of Vaxart in the second quarter valued at $794,000. Finally, Invesco Ltd. raised its stake in shares of Vaxart by 93.1% in the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock valued at $60,000 after buying an additional 70,568 shares during the period. 18.05% of the stock is currently owned by institutional investors.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.